OJJAARA (momelotinib), FDA Approved for the Treatment of Myelofibrosis in Adults with Anemia, Available at Biologics by McKesson

September 20, 2023

CARY, N.C., Sept. 20, 2023Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare diseases, was selected by GSK as a specialty pharmacy provider for OJJAARATM (momelotinib).

OJJAARA, approved by the U.S. Food and Drug Administration (FDA) on September 15, 2023, is an orally administered drug for the treatment of myelofibrosis (MF) in adults with anemia. MF is a rare blood cancer that results from dysregulated JAK-signal transduce and activator of transcription protein signaling and is characterized by constitutional symptoms, splenomegaly, and progressive anemia. Myelofibrosis affects approximately 20,000 patients in the U.S., with about forty percent of patients already anemic at the time of diagnosis and nearly all patients estimated to develop anemia eventually.1.2

“OJJAARA addresses the significant unmet medical needs of patients with MF and provides an additional option for treatment,” said Ela Lourido, general manager and vice president, Specialty Pharmacy Solutions, McKesson. “Biologics by McKesson is proud to be chosen as a specialty pharmacy provider by GSK to offer this important medication to patients who need it.”

Biologics by McKesson is committed to and recognized for its level of customer service as well as its innovative, high-touch, and multidisciplinary approach. Putting patients first in all they do, each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.

For more information about the symptoms, diagnosis, and treatment of MF in adults, please click here. For more information about OJJAARA, including full prescribing information, please click here.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers, and biopharma, so together, they can deliver better care and outcomes for every patient.

1 Chifotides, H.T., Bose, P. & Verstovsek, S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol 15, 7 (2022). https://doi.org/10.1186/s13045-021-01157-4

2 Naymagon, L., & Mascarenhas, J. (2017). Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies. HemaSphere, 1(1), e1. https://doi.org/10.1097/HS9.0000000000000001

Public Relations Contact